Interestingly, recent data from trials of various MS drugs such as IFN-β, fingolimod, and daclizumab indicate that the size of NK cell populations—specifically CD56bright cells—is increased upon treatment (167, 168). The gene discussed is IFNB1; the disease is myeloid sarcoma.